1 citations
,
January 2022 in “European Journal of Pharmacology” In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.
June 2026 in “Oriental Journal Of Chemistry” This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.
1 citations
,
August 2016 This study investigated the cytotoxic effects of DHA derivatives on cancer cell lines and found that didocosahexaenoin was the most potent, inducing apoptosis and producing reactive oxygen species in PC3 prostate carcinoma cells.
19 citations
,
August 2014 in “Journal of Ethnopharmacology” The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.
23 citations
,
December 2013 in “Molecules” This study found that the evodiamine derivative 2-16 exhibited the highest antitumor activity and a broad spectrum of activity against various human cancer cell lines, with improved solubility.
14 citations
,
November 2014 in “European journal of medicinal chemistry” This study identified 30 new compounds with significant androgen receptor binding affinity through a combination of virtual screening and in vitro testing.
This study concluded that pretreatment with finasteride or bicalutamide did not significantly affect the heat sensitivity of prostate cancer cells, although some cell lines showed increased viability at higher temperatures.
8 citations
,
July 2021 in “F1000Research” This review discusses the potential of plant-derived phytochemicals as alternatives to 5-alpha-Reductase inhibitors in treating prostate cancer, highlighting possible benefits like reduced side effects, but it reports no new findings.
January 2016 in “Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)” This study demonstrated that a light-activated RNAi approach using hollow gold nanoshells effectively targets human prostate cancer cells with reduced off-target toxicity and material use compared to standard methods.
This study found that PLX, a mixture of tomato extract and chitooligosaccharide, may reduce prostate weight in testosterone-induced BPH in rats, suggesting it could act as a 5α-reductase inhibitor.
February 2013 in “Americanae (AECID Library)” In this study, finasteride exposure in human prostatic cell lines did not affect cell proliferation but significantly reduced MMP activity and increased TIMP expression, potentially inhibiting tumor cell invasion and metastasis.
This study synthesized new heterocyclic steroid derivatives and reported their promising antiproliferative activity against breast and prostate cancer cell lines, highlighting selectivity and impact on signaling pathways even in cells resistant to certain treatments.
72 citations
,
January 2003 in “American Journal of Pathology” This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.
June 2023 in “SPIRE - Sciences Po Institutional REpository” This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.
12 citations
,
June 2013 in “The Prostate” This study found that dutasteride more effectively inhibited androgen receptor signaling and reduced cell growth compared to finasteride in prostate cancer cell models, with varying sensitivities across different cell lines.
August 2025 in “Therapeutics” In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
August 2023 in “Frontiers in Oncology” This review highlights recent advancements in prostate cancer treatments, particularly new drugs targeting signaling pathways and showing promise in clinical trials, but notes the high recurrence rate of castration-resistant cancer post-therapy, requiring ongoing efforts for effective solutions.
January 2017 in “Anais do 5º Encontro Brasileiro para Inovação Terapêutica” This study found that Dysphania ambrosioides oil exhibited cytotoxicity against U-937 lymphoma cells, indicating potential activity that warrants further investigation.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” This study suggests that the adrenal gland may contribute to prostate cancer treatment resistance and indicates potential steroid production or dependency in ovarian cancer.
4 citations
,
January 2023 in “Proteomes” This review explores the complex, context-dependent roles of tumor-secreted proteins and suggests that some proteins traditionally seen as tumor-promotive may act as tumor-suppressors in different environments, emphasizing the influence of cell fitness and treatment exposure.
3 citations
,
May 2017 in “Bioorganic & medicinal chemistry letters” This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.
19 citations
,
December 2016 in “The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics” This study found that multiple ion channel modulators, used here at clinical concentrations, increased intracellular calcium release in prostate and breast cancer cell lines.
October 2025 in “Scientific Reports” This study found that the extracts of Serenoa repens, when evaluated through chemical, biological, and in silico methods, demonstrated anti-inflammatory, pro-apoptotic, and anti-androgenic activities against prostate cancer cell lines, suggesting potential therapeutic benefits and directing future pharmaceutical development.
8 citations
,
January 2013 in “Medicinal chemistry” This study reported that among 10 tested 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole compounds, compound 4c showed the highest activity against cancer cell lines, with a 95.37% average growth rate.
3 citations
,
March 2018 in “BMC Cancer” This study found that androgenic alopecia was associated with a decreased risk of testicular germ cell tumors but a potential increased risk of high-grade prostate cancer.
63 citations
,
December 2013 in “PLoS ONE” This study suggests that finasteride may reduce the aggressiveness and invasion of prostate tumors, with effects potentially differing based on the androgen responsiveness of the patient's prostate cells.
10 citations
,
May 2007 in “Oncology Reports” This study found that increased metastatic ability in colorectal cancer in a rat model was linked to changes in expression of multiple genes, including TGF-beta, PDGFb, and Rho B.
1 citations
,
October 2024 in “Journal of King Saud University - Science” In this in vitro study, extracts from Tridax procumbens demonstrated potential antioxidant and anticancer activity against various human cancer cell lines, with notable efficacy in specific fractions.